Financing led by Company K Partners with participation from SV Investment, Flexus Partners and existing investors Proceeds to support continued clinical development of novel oncolytic immunotherapy VET3-TGI KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the closing of a $14 million extension of its Series A financing. The financing was led by Company K Partners, with participat

Novartis Venture Fund joins Kynexis’ existing investor syndicate, supporting the Company’s vision of becoming a leading late-stage cognition company Financing supports Phase 2 close-out activities and preparation for registrational studies of KYN-5356, an investigational, potential first-in-class KAT-II inhibitor, in cognitive impairment associated with schizophrenia (CIAS) Company has completed enrollment in ongoing Phase 2 proof-of-concept study in CIAS and remains on track to report topline

Sandoz and Shanghai Henlius Biotech are expanding their existing oncology biosimilars partnership in a deal that could generate up to $322 million for the Chinese drugmaker. The strategic tie-up covers up to 10 proposed monoclonal antibody and antibody-drug conjugate biosimilars, with a majority of the programmes still in early development. Under the deal announced Monday, Sandoz will receive exclusive rights to register and commercialise the partnered products outside China. Henlius, using it

LEO Pharma is set to acquire exclusive global rights to dersimelagon (MT-7117), an investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), from Tanabe Pharma. As part of the deal announced Tuesday, LEO will pay Tanabe $435 million in upfront and near-term milestone payments, with the latter also eligible for additional downstream milestones, alongside tiered sales royalties. Dersimelagon is a once-daily, oral melanocortin 1 receptor (MC1R) agonist des

Phase 1b/2a clinical trial assessing safety and efficacy of LTX-001 in adults with schizophrenia initiated Financing advances LTX-001 through initial readout from Phase 1b/2a trial and progresses LTX-002 through additional dosing cohorts of ongoing Phase 1/2 trial in ALS Aug. 17, 2026 -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A financing. The ro

Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug pipeline. The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026. The latest funding brings the total capital raised by the company to $62m. The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Da

Forge Life Science Partners leads $50 million Series B financing Lead program is an oral, selective IGF-1R inhibitor for thyroid eye disease Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced today that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongsi

Redx Pharma is making its second attempt to go public in a reverse merger, announcing Monday that it will combine with Skye Bioscience to create a new company that will trade on NASDAQ as Fibrx Therapeutics. The deal, expected to close in the fourth quarter, comes more than three years after Redx first tried to combine with another drugmaker. In early 2023, it moved to merge with Jounce Therapeutics, but Concentra Biosciences countered with a takeover bid, ultimately winning out over Redx. Red

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. Aug. 10, 2026 -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial closing, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Direc

As the pharmaceutical industry works to accelerate every aspect of the drug development process, Dash Bio is leveraging automation to speed up one specific step that is still largely manual — the lab-based testing needed to establish a compound's safety and pharmacokinetic profile using preclinical and clinical samples. The service provider on Monday raised a $30-million series A, led by Oak HC/FT, to scale its commercial bioanalysis platform and expand its assay offerings. Existing investors F